On March 7, 2023, Sir Marc Feldmann, Ph.D. provided notice to the Board of Directors of 180 Life Sciences Corp. (the “ Company ”, “ we ” and “ us ”) of his resignation as a member of the Board of Directors, effective on the same date (March 7, 2024).
the Board of Directors of the Company appointed Omar Jimenez and Ryan L. Smith (collectively, the “ Appointees ” and the “ Appointments ”) as members of the Board of Directors (“ Board ”), which Appointments were effective as of the same date.
the Board of Directors of the Company appointed Omar Jimenez and Ryan L. Smith (collectively, the “ Appointees ” and the “ Appointments ”) as members of the Board of Directors (“ Board ”), which Appointments were effective as of the same date.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Sir Marc Feldmann resigned as Director at FORUM MARKETS Inc.
Action
resigned
Role
Director
Exact text from the filing
On March 7, 2023, Sir Marc Feldmann, Ph.D. provided notice to the Board of Directors of 180 Life Sciences Corp. (the “ Company ”, “ we ” and “ us ”) of his resignation as a member of the Board of Directors, effective on the same date (March 7, 2024).
Omar Jimenez was appointed as Director at FORUM MARKETS Inc.
Action
appointed
Role
Director
Exact text from the filing
the Board of Directors of the Company appointed Omar Jimenez and Ryan L. Smith (collectively, the “ Appointees ” and the “ Appointments ”) as members of the Board of Directors (“ Board ”), which Appointments were effective as of the same date.
Ryan L. Smith was appointed as Director at FORUM MARKETS Inc.
Action
appointed
Role
Director
Exact text from the filing
the Board of Directors of the Company appointed Omar Jimenez and Ryan L. Smith (collectively, the “ Appointees ” and the “ Appointments ”) as members of the Board of Directors (“ Board ”), which Appointments were effective as of the same date.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.